amylobarbitone sodium 50 mg and 100 mg, and placebo each given thrice daily (Lader & Wing 1966) . Thirty patients with anxiety states each received three of the five treatments in a balanced incomplete block design, each treatment being given for one week with double-blind procedure. Assessments-of symptoms were carried out daily by the patients and weekly by a psychiatrist. The changes with treatment of the categories of 'physical' symptoms (e.g. palpitations) and 'situational' anxiety (e.g. in crowded surroundings) are shown to the left of Fig 3. A greater placebo effect is apparent in the self-ratings than the psychiatrist's ratings. Whereas chlordiazepoxide appears slightly more effective than barbiturate in lessening ratings of physical symptoms, the reverse obtains for the situational anxiety symptoms. Unwanted effects such as sleepiness were almost equally common for the two drugs at each of the two dosage levels. Physiological recordings were carried out at the end of each week's treatment: decrease in the number of spontaneous skin resistance fluctuations, i.e. a diminution in the level of alertness, is produced by both sedative drugs with chlordiazepoxide marginally more effective at each dosage level. It was concluded that the potency ratio of the two drugs was of the order of 1 mg of chlordiazepoxide to 7 mg of amylobarbitone sodium. However, the drugs had actually been given in approximately this ratio. Thus, potency considerations had been obviated and efficacy comparisons could be legitimately made. As the 'profiles' of the two drugs were so similar, there was no evidence that one drug was generally more efficacious than the other under the conditions of the experiment.
Conclusions
Certain scientific precautions in the clinical evaluation of drugs have been repeatedly advocated (Hill 1960 , Lasagna 1955 including the random allocation of patients to the groups administered the standard and experimental drugs, the use of the double-blind procedure, and the appropriate statistical analyses. Notwithstanding the application of such scientific methods, it appears that the basic discipline of pharmacology offers only part-solutions to the problem of the comparison of drugs in psychiatry.
The choice of suitable criteria for assessment of drug effects and the setting of acceptable incidences for unwanted effects remain dependent on clinical maturity and experience. Perhaps the most important decision of all is one which remains a value-judgment to the greatest extent. How much superior to an established remedy must a new one be to supplant it? This factor has been dubbed 'determinacy': a trial is determinant if the results with the new drug are sufficiently superior to those with the old for its general adoption to represent not only a significant, in the statistical sense, but a worth-while therapeutic advance (Atkins 1966) . Nevertheless, the information upon which this ultimate clinical decision is made must be amassed using scientific methods. In this way, the clinical pharmacologist and the experienced psychiatrist can collaborate to the ultimate benefit of their patients and of therapeutics. There may be many paths leading to advances in treatment but, in Hedley Atkins' words (1966), 'there is only one high-road to an increase in therapeutic knowledge, and that is the controlled clinical trial'. Almost all evaluations of therapy are now made within the artificial confines of drug trials, and there have been few attempts to determine factors which influence the use of drugs made by observers not implicated in the treatment or its outcome (Martin 1957 , Wilson et al. 1963 .
In carrying out a study of this kind monoamine oxidase inhibitors (MAOI) were selected because they provided a paradigm of the familiar passage from unbridled enthusiasm to increasing scepticism which marks the fate of many drugs (Hollister 1965).
Historical Background
The MAOI owed their introduction to a chance observation, when chest physicians noted the euphoriant effect of iproniazid (Kamman et al. 1953) . This came at a time of need created both by dissatisfaction with the amphetamines for treatment of depression and the availability of chemical control for other forms of mental illness. Coincidentally iproniazid was found to inhibit monoamine oxidase (Zeller & Barsky 1952) and and so might increase brain amine levels. Thus chance observation, widely felt need, and plausible biochemical rationale were sufficient to ensure easy acceptance of the MAOI without the added impetus provided by uncritical advertising (Sargant 1961) and uncontrolled clinical trials.
The MAOI were first introduced as possible cures for 'endogenous' depressions (Kline 1958) , often in quite high dosage (British Medical Journal 1960), but earlier evaluations made it clear that MAOI did not rival ECT (Sargant 1961 , Rees 1960 , Rees & Davies 1961 . They became used instead for milder forms of affective illness encountered in outpatients, similar to those once treated with amphetamines and barbiturates. Phenelzine and tranylcypromine (Marks 1965) are close structural congeners of amphetamine but Hare et al. (1962) suggested that the MAOI act as sedatives, whilst others have claimed that they are effective in illnesses once diagnosed as 'anxiety states' (Dally & Sargant 1959) .
The relative use of the MAOI in the Maudsley Hospital has declined from half to one-third of antidepressants since 1963 when concern was aroused by hypertensive side-effects (Blackwell 1963) . Tranylcypromine suffered most because of this side-effect ( Fig 1) and its use fell sharply, but was offset by a compensatory increase in phenelzine, isocarboxazid, and iproniazid, suggesting that clinicians switched from one MAOI to another in search of a safe effective remedy. This pointed to the existence in the clinician's mind of a type of patient for whom these drugs were the best available treatment.
It was this situation that the study set out to examine in detail.
Method
The series comprised all (138) outpatients prescribed MAOI during January and February 1965; it included a cohort of 43 new patients (10 % of all outpatients). Eighteen months elapsed before the evaluations were completed.
The response to therapy was rated on a 6 point scale from the notes at key intervals following its initiation and each case was also allocated an overall 'good' or 'poor' response to therapy.
Results
Population characteristics: Half the population had suffered a previous psychiatric illness and half had been ill for over a year. In three-quarters of them the physician or patient attributed some oetiological significance to environmental events.
The features of illness most commonly found were anxiety (psychic, phobic and somatic), variability, irritability, initial insomnia and difficulty in concentration.
A population weighted in this way towards reactivity, chronicity and variability poses considerable difficulty in drug evaluation. Moreover the preponderance of physical complaints makes the patient swift to attribute adverse effects to drug therapy and the clinician correspondingly prone to minimize them.
Type ofillness treated: The diagnoses were depression in 70 %, anxiety 15 %, and 15 % were miscellaneous. Extreme forms of illness were lacking and so-called 'neurotic' complaining common.
Treatment itself influenced diagnosis in 10 % of patients. Hare (1963) noted an increase in the diagnosis of depression, matched by a fall in other diagnoses, possibly because depressive features were highlighted in anticipation of or following response to 'antidepressive' medication.
Individual clinician'sprescribing habits:
(1) Extent of drug use: Fifteen out of 17 clinicians used MAOI but 8 were low users, 6 high users, and one was a particularly heavy user. Onequarter of the drugs were used by a single clinician (A) who treated 7 % of outpatients; and three-quarters by less than half the clinicians who saw only a third of all outpatients.
(2) Method of drug use: Only clinician A used iproniazid and clinicians B and C isocarboxazid. In the series phenelzine was preferred to tranylcypromine in a 3: 2 ratio, but clinician A avoided tranylcypromine almost entirely (Fig 2) . Tlhe MAOI were used after the failure of other treat- (3) Type of patient treated: The sex ratio varied from 80 % females (clinician C) to 50% (clinician D). In age clinician B's patients resembled the series, but A had a preponderance in the under 35s, C in the over 35s, and D in the under 45s. Clinician D had twice as many severe personality disorders and less than one-third as many normal personalities. Distribution of diagnoses differed in each clinician's patients. In the duration of illness A's sample conformed to the series whilst C and D had fewer and B had more long duration illnesses.
Some Factors Related to Outcome Patient, illness and treatment characteristics: A good outcome was obtained in three-quarters of the men, compared with halfthe women (P <0 05). In the Medical Research Council trial (MRC Clinical Psychiatry Committee 1965), men also did better with tablets of all kinds.
Anxious personality and somatic anxiety were related to good outcome, and variability with poor response.
An anxiolytic increased good outcome from half to two-thirds (P<0-1) and chlordiazepoxide was superior to diazepam (P<0-02). Patients did better given an MAOI first (P<0-1) instead of after failing other antidepressant therapy (ECT or tricyclic drug). Those who failed to respond to an anxiolytic alone did equally well as those without previous treatment. Iproniazid and Parstelin were associated with better outcome than the three other drugs used (P <0 1).
Clinicians and outcome: The difference in outcome between the 5 clinicians whose results were better than expected and the 10 whose outcome is below the whole series is significant (P <0-05) ( Table 1) .
A comparison between patients treated by 5 'successful' clinicians and those treated by the remainder determined the distribution in each population of features in the patients, illness or treatment already shown to favour good outcome ( Table 2) .
The features in patients and illness were evenly distributed between the groups but successfu 
Some Factors Influencing Drug Use
Duration of illness and treatment: Giel et al. (1964) found 61 % of neurotic outpatients recovered in two years however treated; in this study good outcome after eighteen months was 62 %. Fig 3 (insert) plots attendances by triennium outpatients against percentage remaining in treatment ; 42 % attended once, three-quarters less than five times, and a quarter attended more often. This curve has remaind unchanged during the antidepressant drug era with no alteration in rapidity of discharge or of hospital-dependent patients.
The two broad lines (Fig 3) patientsupper line) and the cohort (43 patientslower line). Of 138 patients two-thirds took amine oxidase inhibitors for six months, a half for twelve months, a third for eighteen months, a quarter for two years and one in ten for three years or more. Of the cohort cases, under a half remained at three months, a third at six months and 9 % at eighteen months. Separate curves for good and poor outcome show that duration of treatment is poorly related to drug response.
Response specificity: The Food and Drugs Administration reinstated tranylcypromine because certain patients responded only to this drug (Sadusk 1964) and Pare (1965) suggested that specific responders to MAOI exist.
In this study patients previously responding to an MAOI did no better than patients treated for the first time. Failure to respond to a tricyclic reduced success to 51 % compared with 70 % for previously untreated patients. Lastly, only 24% responded to a tricyclic derivative after failure of an MAOI. These findings suggest patients may be drug sensitive or drug resistant, rather than specific responders.
Side-effects: Thirty-three patients (24%) experienced side-effects, leading to a change of therapy in4 cases. These were predominantly hypotension, insomnia, impotence and severe headache with little difference between individual drugs.
Incidence of hypertensive crises ranges from 1 % to 20% (Blackwell et al. 1967) . In this study the case records suggested a hypertensive crisis in 5 % and the manner in which physical complaints clouded the significance of side-effects was readily apparent.
A questionnaire given to 50 patients revealed that 58 % were avoiding cheese and 26 % Marmite; 44 % knew the drug they were taking. Patients of clinicians making scant use of MAOI were more often aware of the name and possible dangers of their tablets. Summary and Appraisal ofPrescribing Habits A hundred and thirty-eight outpatients taking MAOI appeared similar to those once prescribed barbiturates or amphetamine. Evaluation of the MAOI was complicated by population characteristics and influence of therapy on diagnosis.
Ten per cent of new outpatients received MAOI, but extent and method of use varied widely between clinicians, as did the type of patient each clinician treated. Male sex, somatic anxiety, anxious personality and concurrent use of anxiolytics favoured good outcome but clinicians' results depended more upon use of MAOI as drugs of first choice, and the type of drug, and less on the sort of patient treated.
Duration of treatment was prolonged, and poorly correlated with outcome. MAOI have not influenced duration of outpatient attendance, and specific response was not apparent. The popularity of Parstelin may have been due to its combining an anxiolytic; phenelzine has regained primacy due to its relative safety. The risks of MAOI are not successfully communicated and overall decline in use is probably accounted for by clinicians turning first to tricyclics. This may become reinforced by unsuccessful use of MAOI as second choice therapy in refractory cases.
Only further studies on other antidepressants will determine how much outcome depends on the drug and how much on the peculiarities of the outpatient population taking them.
(A fuller report of this work will be published elsewhere.)
